Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 N549K |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 - WAC FGFR2 M537I FGFR2 M538L FGFR2 N549H FGFR2 N549K FGFR2 N549T FGFR2 L550F FGFR2 V564F FGFR2 V564I FGFR2 E565A FGFR2 D650Y FGFR2 N652S FGFR2 K659Q | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-WAC fusion experienced disease progression after 5.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, M537I, M538L, N549H, N549T, N549K, L550F, V564F, V564I, E565A, D650Y, N652S, K659Q (PMID: 34250419). | 34250419 |
FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion experienced disease progression after 10.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K, N549D, N549H, V564F, V564I, V564L, E565A, L617V, L617F, K659M, Q746L (PMID: 34250419). | 34250419 |
FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on Truseltiq (infigratinib) treatment (PMID: 28034880). | 28034880 |
FGFR2 K310R FGFR2 N549K | endometrial carcinoma | no benefit | RO4987655 | Preclinical - Cell culture | Actionable | In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159). | 26438159 |
FGFR2 K310R FGFR2 N549K | endometrial cancer | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Futibatinib (TAS-120) treatment led to inhibition of cell proliferation in an endometrial cancer cell line harboring FGFR2 K310R and FGFR2 N549K in culture (PMID: 32973082). | 32973082 |
FGFR2 K310R FGFR2 N549K | endometrial carcinoma | no benefit | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159). | 26438159 |
FGFR2 K310R FGFR2 N549K | endometrial cancer | sensitive | Debio 1347 | Preclinical | Actionable | In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980). | 25169980 |
FGFR2 K310R FGFR2 N549K | endometrial carcinoma | sensitive | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520). | 20338520 |
FGFR2 K310R FGFR2 N549K | endometrial carcinoma | no benefit | RO5126766 | Preclinical - Cell culture | Actionable | In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159). | 26438159 |
FGFR2 - CCDC170 FGFR2 N549K FGFR2 K641R | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-CCDC170 experienced disease progression after 6.9 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K and FGFR2 K641R (PMID: 33218975; NCT02924376). | 33218975 |
FGFR2 - NRBF2 FGFR2 N549K | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-NRBF2 experienced disease progression after 13.1 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K (PMID: 33218975; NCT02924376). | 33218975 |
FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase I trial (FIGHT-101), a cholangiocarcinoma patient harboring FGFR2-CCDC6 experienced disease progression after initially responding to Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K, FGFR2 N549D, and FGFR2 V564I (PMID: 35176457; NCT02393248). | 35176457 |
FGFR2 - NRAP FGFR2 N549K FGFR2 V564L | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-NRAP fusion experienced disease progression after seven months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K and V564L (PMID: 34250419). | 34250419 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|